Security key
M47238148
Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (GLMD)
CUSIP: M47238148
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Ordinary Shares, NIS 1.80 par value per share
- Total 13F shares
- 72,824
- Total 13F value
- $102,011
- Share change
- -3,163
- SEC-reported price per share
- $1.38
- Number of holders
- 13
- Value change
- -$18,462
- Number of buys
- 3
- Number of sells
- 7
- Shares outstanding
- 5,591,387
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
13
Top holders
10
GLMD full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Previous quarter: Q2 2025
Galmed Pharmaceuticals Ltd. SEC filings
Galmed Pharmaceuticals Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP M47238148
Recent filing periods:
Ownership snapshot
Top reported holders of GLMD - Galmed Pharmaceuticals Ltd. - Ordinary Shares, NIS 1.80 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
CVI Investments, Inc.
Disclosed value leader
CVI Investments, Inc.
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
Lead comparable stake: 3.1%
13D/G row: CVI Investments, Inc.
Showing 1-6 of 15 holder rows.
Quick read
CVI Investments, Inc. leads the comparable SEC ownership view at 3.1%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens CVI Investments, Inc.'s linked filing trail.
Comparable ownership
Top 5
CVI Investments, Inc.
3.1%
Allen Baharaff
2.6%
MORGAN STANLEY
0.6%
Schonfeld Strategic Advisors LLC
0.41%
Cambridge Investment Research Adv...
0.18%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| CVI Investments, Inc. |
13D/G
|
3.1%
|
$346,666
173,333 shares
|
$0 | 30 Sep 2025 |
| Allen Baharaff |
13D/G
|
2.6%
|
$60,455
44,128 shares
|
$0 | 31 Dec 2024 |
| MORGAN STANLEY |
13F
Company
|
0.6%
|
$61,774
33,573 shares
|
— | 30 Jun 2025 |
| Schonfeld Strategic Advisors LLC |
13F
Company
|
0.41%
|
$42,676
23,194 shares
|
— | 30 Jun 2025 |
| Cambridge Investment Research Advisors, Inc. |
13F
Company
|
0.18%
|
$19,000
10,132 shares
|
— | 30 Jun 2025 |
| UBS Group AG |
13F
Company
|
0.12%
|
$12,702
6,903 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
13
Shares
72,824
Rows available
13
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
14
Q3 2025 holders
13
Holder diff
-1
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend